Compare · HAE vs WST
HAE vs WST
Side-by-side comparison of Haemonetics Corporation (HAE) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HAE and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.35B, about 7.3x HAE ($3.05B).
- Over the past year, HAE is down 2.2% and WST is up 51.0% - WST leads by 53.2 points.
- HAE has been more active in the news (11 items in the past 4 weeks vs 6 for WST).
- HAE has more recent analyst coverage (25 ratings vs 15 for WST).
- Company
- Haemonetics Corporation
- West Pharmaceutical Services Inc.
- Price
- $67.27-0.99%
- $315.91-2.11%
- Market cap
- $3.05B
- $22.35B
- 1M return
- +12.04%
- +6.16%
- 1Y return
- -2.22%
- +51.02%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 1991
- News (4w)
- 11
- 6
- Recent ratings
- 25
- 15
Haemonetics Corporation
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest HAE
- SEC Form SD filed by Haemonetics Corporation
- Haemonetics upgraded by BofA Securities with a new price target
- SEC Form 10-K filed by Haemonetics Corporation
- EVP and General Counsel Basil Michelle L covered exercise/tax liability with 2,913 shares and was granted 28,424 shares, increasing direct ownership by 59% to 68,829 units (SEC Form 4) (tax withholding)
- EVP, Chief Operating Officer Chan Frank was granted 27,535 shares and covered exercise/tax liability with 546 shares, increasing direct ownership by 454% to 32,936 units (SEC Form 4) (tax withholding)
- EVP, Chief Financial Officer Darecca James covered exercise/tax liability with 2,505 shares and was granted 29,312 shares, increasing direct ownership by 97% to 54,444 units (SEC Form 4) (for withholding tax)
- VP, Chief Accounting Officer Maunsell Farris Maryanne covered exercise/tax liability with 197 shares and was granted 2,220 shares, increasing direct ownership by 45% to 6,501 units (SEC Form 4) to cover taxes
- EVP, Chief Commercial Officer Galvin Roy covered exercise/tax liability with 879 shares and was granted 27,535 shares, increasing direct ownership by 202% to 39,882 units (SEC Form 4) to satisfy withholding tax
- SVP, Human Resources Miller Laurie A. covered exercise/tax liability with 948 shares and was granted 13,323 shares, increasing direct ownership by 43% to 41,300 units (SEC Form 4) to cover withholding tax
- President & CEO Simon, Christopher covered exercise/tax liability with 9,681 shares and was granted 78,344 shares, increasing direct ownership by 18% to 444,704 units (SEC Form 4) (withholding obligation)
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)
- Director Lai Goldman Myla was granted 791 shares, increasing direct ownership by 4% to 20,435 units (SEC Form 4)